syringe and bottle

Hastings Center News

Mildred Solomon on Controversial Duchenne Drug Approval

Writing in the Health Affairs Blog, Hastings Center president Mildred Solomon says that the Food and Drug Administration’s controversial decision to approve the first drug for Duchenne muscular dystrophy is defensible, but only if there is adequate follow through. Read the post here.

The Hastings Center has never shied away from the toughest ethical challenges faced by society.

LET US SHARE OUR EXPERIENCES WITH YOU

Interests